We are live on ! Find out more
MACK

Merrimack Pharmaceuticals, Inc.
MACK

Delisted

MACK was delisted on the 17th of May, 2024.

Back to rankings

143 hedge funds and large institutions have $657M invested in Merrimack Pharmaceuticals, Inc. in 2014 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 45 increasing their positions, 44 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

65% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 20

39% more capital invested

Capital invested by funds: $474M → $657M (+$183M)

8% more funds holding

Funds holding: 132 → 143 (+11)

2% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 44

31% less call options, than puts

Call options by funds: $1.79M | Put options by funds: $2.58M

Holders
143
Holders Change
+11
Holders Change %
+8.33%
% of All Funds
3.81%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
33
Increased
45
Reduced
44
Closed
20
Calls
$1.79M
Puts
$2.58M
Net Calls
-$793K
Net Calls Change
-$2.86M

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$9.22M
2
BIT
BlackRock Institutional Trust
California
+$6.6M
3
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
+$5.39M
4
TC
TFS Capital
Pennsylvania
+$4.41M
5
BFA
BlackRock Fund Advisors
California
+$3.74M

Top Sellers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
-$13.5M
2
State Street
State Street
Massachusetts
-$4.29M
3
Jane Street
Jane Street
New York
-$2.83M
4
SIP
Stoneridge Investment Partners
Pennsylvania
-$2.59M
5
New York State Common Retirement Fund
New York State Common Retirement Fund
New York
-$1.94M
Name Holding Trade Value Shares
Change 		Change in
Stake
William Blair & Company
26
William Blair & Company
Illinois
$4.35M -$361K -4,950 -9%
CCM
27
Cadence Capital Management
Massachusetts
$3.94M +$1.44M +19,815 +81%
BA
28
BlackRock Advisors
Delaware
$3.89M +$1.31M +18,050 +70%
GC
29
Guggenheim Capital
Illinois
$3.83M +$3.14M +43,134 New
CC
30
Cannell & Co
New York
$3.69M +$2.42M +33,212 +400%
Invesco
31
Invesco
Georgia
$3.67M +$1.14M +15,696 +61%
Goldman Sachs
32
Goldman Sachs
New York
$3.48M -$16.3K -224 -0.6%
Charles Schwab
33
Charles Schwab
California
$3.26M +$147K +2,022 +6%
ACM
34
Alpha Capital Management
Texas
$3.17M +$65K +892 +3%
BIM
35
BlackRock Investment Management
Delaware
$3.04M -$22.1K -304 -0.9%
JP Morgan Chase
36
JP Morgan Chase
New York
$2.97M -$752K -10,326 -24%
Renaissance Technologies
37
Renaissance Technologies
New York
$2.89M -$609K -8,363 -20%
RFC
38
Russell Frank Company
Washington
$2.53M +$291K +4,001 +16%
Wellington Management Group
39
Wellington Management Group
Massachusetts
$2.52M +$582K +7,983 +39%
SIM
40
Spark Investment Management
New York
$2.09M +$871K +11,960 +104%
California State Teachers Retirement System (CalSTRS)
41
California State Teachers Retirement System (CalSTRS)
California
$2.06M +$7.14K +98 +0.4%
Susquehanna International Group
42
Susquehanna International Group
Pennsylvania
$1.96M +$736K +10,102 +85%
UBS Group
43
UBS Group
Switzerland
$1.89M +$1.55M +21,288 New
Axa
44
Axa
France
$1.87M +$1.53M +21,058 New
CT
45
Cambridge Trust
Massachusetts
$1.86M -$139K -1,906 -8%
JMPWA
46
JP Morgan Private Wealth Advisors
California
$1.83M -$394K -5,415 -21%
AllianceBernstein
47
AllianceBernstein
Tennessee
$1.82M – – –
American Century Companies
48
American Century Companies
Missouri
$1.75M +$1.43M +19,632 New
Royal Bank of Canada
49
Royal Bank of Canada
Ontario, Canada
$1.72M +$368K +5,058 +36%
SIP
50
Stoneridge Investment Partners
Pennsylvania
$1.66M -$2.59M -35,522 -66%
1
2
3 4 5

MACK Hedge Fund Activity: Q4 2014 in Review

143 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q4 2014, worth a combined $657M — up 39% from $474M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new MACK positions and 20 closed out — a net gain of 13 holders — while 45 added to existing stakes and 44 trimmed.

The largest buyer was Vanguard Group, adding an estimated $9.22M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $13.5M sold.

  • 143 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q4 2014, up from 132 in Q3 2014.
  • Funds reported $657M of Merrimack Pharmaceuticals, Inc. stock for Q4 2014, up 39% quarter-over-quarter.
  • 33 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q4 2014 and 20 closed out, a net change of +13 holders.
  • The largest Merrimack Pharmaceuticals, Inc. buyer in Q4 2014 was Vanguard Group, an estimated $9.22M added.
  • The largest Merrimack Pharmaceuticals, Inc. seller in Q4 2014 was Consonance Capital Management, an estimated $13.5M sold.

Based on aggregated 13F filings for Q4 2014.